MedWatch

Analyst: Darzalex sales figures could result in Genmab upgrade

Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.

Photo: Sydbank/PR

The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.

The total market sales from the Johnson & Johnson-owned Janssen, which obtained Darzalex through an in-licensing agreement, could very well end up also exceeding the USD 5.6-5.9bn estimate that Genmab has included in its 2021 guidance.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs